Skip to main content

LIVE

RARE

Ultragenyx Pharmaceutical Inc.

RARE

NASDAQ·Healthcare·Biotechnology·Mkt cap $1.5B

$15.30

+3.03%

P/E

-5.58

Mkt Cap

$1.5B

52-Wk Range

$13.81–$39.89

52-Week Range

$13.81 - $39.89

P/E

-5.58

Fwd P/E

-3.83

Beta

0.32

Div Yield

0.00%

Avg Vol

2.6M

Shares Out

Mkt Cap

$1.5B

Price action

Price chart

Down 51.4% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

No bull reasons captured for this rating yet.

Bear Case

1 risk

  • Low volatility (beta 0.3).

Growth

Strong growth ahead

Value

Deep value opportunity - significant discount to sector peers

Momentum

Falling

-29.1% over 3m

Quality

Excellent

Solid business

Dividend

None

No dividend

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 3, 2026

Q3 26 RECAP

AUG 4, 2026

Reported EPS of -$0.90 vs -$1.22 consensus (+26.2% surprise). Revenue of $214.0M vs $183.1M expected (+16.9%). Beat on both top and bottom lines.

EPS beat +26.2%
Rev beat +16.9%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+26.2%

Revenue trend · last 2Q

+29%

Q1 26

Q2 26

$136.0M

$214.0M

Margins · last 2Q

Gross

84.1%

Operating

-35.0%

Profit

-43.0%

Wall Street consensus

10 analysts · 60% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

6

60%

Hold

4

40%

Sell

0%

Median Price Target

Latest: Barclays · Sep 4, 2026

vs Industry

How RARE stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.